Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease

Kettunen, Petronella; Bjerke, Maria; Eckerström, Carl; Jonsson, Michael; Zetterberg, Henrik; Blennow, Kaj; Svensson, Johan; Wallin, Anders

Published in:
Alzheimer's & Dementia

DOI:
10.1002/dad2.12296

Publication date:
2022

License:
CC BY-NC

Document Version:
Final published version

Link to publication

Citation for published version (APA):
Kettunen, P., Bjerke, M., Eckerström, C., Jonsson, M., Zetterberg, H., Blennow, K., Svensson, J., & Wallin, A. (2022). Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease. Alzheimer's & Dementia, 14(1), [e12296]. https://doi.org/10.1002/dad2.12296

Copyright
No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

Take down policy
If you believe that this document infringes your copyright or other rights, please contact openaccess@vub.be, with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.
Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease

Petronella Kettunen1 | Maria Bjerke2,3 | Carl Eckerström1,4 | Michael Jonsson1 | Henrik Zetterberg1,5,6,7,8 | Kaj Blennow1,5 | Johan Svensson9,10 | Anders Wallin1

1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2Laboratory of Neurochemistry, Department of Clinical Biology and Center for Neurosciences, Universitair Ziekenhuis Brussel, Brussels, Belgium
3Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
4Department of Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
6Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
7UK Dementia Research Institute at UCL, London, UK
8Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
9Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
10Region Västra Götaland, Department of Internal Medicine, Skaraborg Central Hospital, Skövde, Sweden

Correspondence
Petronella Kettunen, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Email: petronella.kettunen@neuro.gu.se

Abstract

Introduction: Subcortical small-vessel disease (SSVD) is the most common vascular cognitive disorder. However, because no disease-specific cerebrospinal fluid (CSF) biomarkers are available for SSVD, our aim was to identify such markers.

Methods: We included 170 healthy controls and patients from the Gothenburg Mild Cognitive Impairment (MCI) study clinically diagnosed with SSVD dementia, Alzheimer’s disease (AD), or mixed AD/SSVD. We quantified CSF levels of amyloid-β (Aβ40, Aβ42), as well as soluble amyloid precursor protein (sAPP)-α and sAPP-β.

Results: sAPP-β was lower in SSVD patients than in AD patients and controls. Receiver-operating characteristic (ROC) analyses showed that sAPP-β moderately separated SSVD from AD and controls. Moreover, the CSF/serum albumin ratio was elevated exclusively in SSVD and could moderately separate SSVD from the other groups in ROC analyses.

Discussion: SSVD has a biomarker profile that differs from that of AD and controls, and to some extent also from mixed AD/SSVD, suggesting that signs of blood-brain barrier (BBB) dysfunction and sAPP-β could be additional tools to diagnose SSVD.
1 | BACKGROUND

Vascular cognitive disorder (VCD) and Alzheimer’s disease (AD) belong to the most common cognitive disorders in the elderly population. Several forms of VCD exist but in this article we use the singular denomination for all variants of VCD. VCD is similar to “vascular cognitive impairment” but refers more clearly to phenotypically characteristic subgroups and is broader than “vascular dementia,” as milder forms of cognitive impairment also are included. The subcortical small-vessel type of disease (SSVD) has been estimated to be the most common form of VCD.1,2 The disease affects the small vessels deep in the brain, including perforating arterioles, capillaries, and venules.1,3 In these patients, magnetic resonance imaging (MRI) reveals increased occurrence of cerebral microbleeds (CMBs), infarcts, and lacunes, as well as white matter hyperintensities (WMHs) that correspond to lesions of the brain white matter. Moreover, SSVD patients exhibit reduced executive function, decreased processing speed, and only mild memory loss,3 whereas patients with AD are characterized by disturbances in interpreting sensory information and pronounced loss of memory. However, the clinical phenotype may resemble that of AD. Especially, the continuously progressive disease course is characteristic of both SSVD and AD. There are so far no established disease-specific biochemical markers for SSVD, but the blood-brain barrier (BBB) has been suggested to be involved in the pathogenesis of SSVD.4-7

AD is characterized by the accumulation of extracellular plaques consisting of amyloid beta (Aβ), intracellular tangles composed of hyperphosphorylated tau (p-tau), and synapse degeneration. The clinical symptoms include predominantly memory and language impairments. The amyloid cascade hypothesis is the prevailing hypothesis of the origin of AD.8 The presence of AD neuropathology can be identified by the use of cerebrospinal fluid (CSF) biomarkers. The typical CSF biomarker pattern includes decreased levels of Aβ42 (or Aβ1-42/1-40 to increase specificity for plaque pathology) and increased levels of p-tau181 and total tau (t-tau). Moreover, mixed pathology such as mixed AD/SSVD (also known as mixed dementia) is a common condition, where features of AD and SSVD coexist in the brain.9 Biomarker studies investigating mixed AD/SSVD are few, but in one study, clinically defined mixed AD/SSVD was characterized by a typical AD CSF biomarker profile and an SSVD-like neuropsychological cognitive profile.10

Metabolites derived from the amyloid precursor protein (APP) including different Aβ peptides (e.g., Aβ38, Aβ40, and Aβ42, where “x” indicates any lengths of the peptides), as well as the soluble APP fragments cleaved by α- and β-secretases (sAPP-α and sAPP-β, respectively) have been used to improve the understanding of the amyloid cascade hypothesis in AD, but it is not yet known whether they are altered in SSVD. Although most of the studied APP fragments, excluding Aβ42, are unaltered in AD,11 the results of several studies suggest that these biomarkers (including Aβ42) may be associated with the amount of WMHs.12-16 Consequently, these biomarkers may be altered in SSVD that is characterized by the presence of WMHs. To our knowledge, no studies have yet investigated CSF levels of the whole spectrum of APP metabolites in patients with pure SSVD. Therefore, we investigated a panel of CSF APP metabolites, and in addition, CSF/serum albumin ratio in participants of the Gothenburg Mild Cognitive Impairment (MCI) study.17 We included healthy controls and patients diagnosed with SSVD, AD, and mixed AD/SSVD mild dementia using clinical and biomarker tools.

2 | METHODS

2.1 | Study participants

In this cross-sectional study, we evaluated CSF amyloid biomarkers in 45 healthy controls and 125 patients (SSVD, n = 30; AD, n = 60; and mixed AD/SSVD, n = 35). Patients with other forms of dementia (cortical vascular dementia, primary progressive aphasia, Lewy body dementia, frontotemporal dementia, or unspecified dementia) were excluded. The participants were recruited from the Gothenburg MCI study, a mono-center study of patients seeking help for cognitive complaints at the memory clinic at Sahlgrenska University Hospital.17 The inclusion and exclusion criteria were designed to exclude somatic and psychiatric conditions associated with increased risk of cognitive impairment. Thus the inclusion criteria comprised age >40 and <79 years, Mini Mental State Examination (MMSE) score >19, and self- or informant-reported cognitive decline with a duration ≥6 months. The
RESEARCH IN CONTEXT

1. Systematic Review: The authors performed a literature review of databases of published articles (PubMed and Web of Science), as well as preprint repositories (bioRxiv and medRxiv) and the web, using search terms such as “biomarkers,” “amyloid precursor protein,” “amyloid-$\beta$,” “blood-brain barrier,” “cerebrospinal fluid,” “small vessel disease,” “Alzheimer’s disease,” “mixed dementia,” and “mixed Alzheimer’s disease/small vessel disease.” The limited available publications regarding biomarkers for subcortical small vessel disease or mixed disease indicated the need for the present study.

2. Interpretation: Our findings speak in favor of the concept that subcortical small-vessel disease (SSVD) is a distinct form of vascular cognitive disorder (VCD).

3. Future Directions: Future studies that would help explain our findings include biological and neuropathological analyses of the role of soluble amyloid precursor protein ($s\text{APP}$)-$\beta$ in the healthy and diseased brain, as well as longitudinal analyses of changes of the tested cerebral spinal fluid (CSF) biomarkers.

exclusion criteria included severe somatic disease (e.g., subdural hemorrhage, brain tumor, untreated hypothyroid state, encephalitis, and unstable heart disease), psychiatric disorder (e.g., major affective disorder or schizophrenia), substance abuse, and confusion. The healthy controls were primarily recruited through senior citizen organizations, for example, information meetings on cognitive disorders, and some controls were relatives of the patients. Present, or history of, cognitive decline was an exclusion criterion in the controls; otherwise the exclusion criteria as well as the study procedures were similar as those applied for the patients.

2.2 Diagnostic procedures

The patients were classified using the global deterioration scale (GDS), in which a GDS score of 4 equals mild dementia. The classification into GDS group 4 was based on medical history, checklists, and instruments for cognitive symptoms: (1) Stepwise Comparative Status Analysis (STEP), variables 13 to 20 (memory disturbance, disorientation, reduced abstract thinking, visuospatial disturbance, poverty of language, sensory aphasia, visual agnosia and apraxia); (2) I-FLEX, a short form of the Executive Interview (EXIT) (number-letter task, word fluency, anomalous sentence repetition, interference task, Luria hand sequences, counting task); (3) MMSE; and (4) clinical dementia rating (CDR). The CDR assessment was based on information from both the subject and an informant. Guidelines for GDS 4 were: STEP $>1$, I-FLEX $>3$, CDR $>1.0$, MMSE $\leq 25$. Finally, a consensus decision among the physicians at the clinic was made to determine the appropriate GDS score. Only patients with mild dementia were included in the present study.

The physicians who determined the specific dementia diagnoses according to the research protocol had access to clinical symptomatology and MRI data, but were blinded to neuropsychological test results and CSF biomarker data. AD was diagnosed using the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. More specifically, an AD diagnosis required predominant parietotemporal lobe symptoms and no or mild WMHs using magnetic resonance imaging (MRI). Although diagnoses in the umbrella study were set without taking into account CSF biomarkers, they were revised in the present substudy using these markers. Hence, it was required that AD patients had CSF biomarker levels consistent with an AD profile in agreement with the International Working Group-2 (IWG-2) criteria. Furthermore, clinical SSVD patients with CSF biomarker evidence of AD pathology were considered to fulfill a mixed AD/SSVD diagnosis, and patients with clinical mixed AD/SSVD without CSF biomarker evidence were reclassified to SSVD. Patients with a clinical AD diagnosis, but without CSF biomarker evidence of pathology, were excluded as well as controls with biomarker evidence of AD pathology, when diagnoses were revised using biomarkers. The applied cut-offs for abnormality for the CSF AD biomarkers were $t\text{-tau} > 350\text{ ng/L}$, $p\text{-tau}_{181} > 59\text{ ng/L}$, and $A\beta_{1-42} < 530\text{ ng/L}$.

A clinical SSVD diagnosis was set according to the Erkinjuntti criteria. More specifically, for SSVD, the patient had to have MRI-detected cerebral WMHs, (mild, moderate, or severe according to Fazekas classification) and predominant frontal lobe symptoms. If WMHs were only mild, then SSVD was set only if parietotemporal lobe syndromes were not marked. For an SSVD diagnosis to be made, the CSF AD biomarkers had to be negative (same criteria as above). Mixed AD/SSVD was diagnosed if AD patients also exhibited MRI findings of cerebral WMHs (moderate or severe according to Fazekas classification) with no predominant frontal lobe syndrome, if AD patients exhibited mild degree of WMHs in combination with a marked frontal lobe syndrome, or if SSVD patients showed CSF AD biomarker evidence of AD pathology.

The classification used in the study is in line with the results of the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) in which SSVD dementia, denominated subcortical ischemic vascular dementia, is one of the entities. No patients exhibited post-stroke dementia or multi-infarct dementia.

2.3 Neuropsychological testing

In addition to the tests used for GDS classification, a neuropsychological test battery was administered. We used the delayed recall from the Rey Auditory Verbal Learning Test (RAVLT) to assess episodic memory and the Trail Making Test A (TMT-A) and B (TMT-B) to evaluate visual scanning and complex attention.
2.4 Cerebrospinal fluid sampling and biomarker assessments

CSF samples were drawn at the lumbar vertebrae L3/L4 or L4/L5 interspace with the patients in a fasted state between 08:00 and 10:00 a.m. The first portion of the CSF sample was discarded to avoid blood contamination. In all, 20 mL of CSF was collected in polypropylene tubes and gently mixed by inverting the tube. The CSF was centrifuged at room temperature at 2000 × g for 10 minutes, and then stored at −80°C pending analyses.17

All biomarkers were analyzed at the Clinical Neurochemistry Laboratory in Mölndal, Sweden, by board-certified laboratory technicians who were blinded to the clinical diagnoses and other clinical information. CSF concentrations of Aβ42, the axonal damage marker t-tau, and p-tau181 were measured using sandwich enzyme-linked immunosorbent assays (ELISAs; INNOTEST β-AMYLOID (1-42), INNOTEST hTAU Ag, and INNOTEST PHOSPHO-TAU (181P), respectively; Fujirebio, Gent, Belgium). CSF Aβ40, Aβ38, and Aβ42 concentrations were measured using the MSD V-PLEX Aβ Peptide Panel 1 (4G8) kit (Meso Scale Diagnostics, Rockville, MD, USA). CSF sAPP-α and sAPP-β concentrations were measured using the MSD sAPP-α/sAPP-β duplex assay (Meso Scale Diagnostics). Two internal control CSF samples (aliquots of pooled CSF) were analyzed in each run as internal quality controls to control for between-assay variability, which was <10% for all markers.17 Serum and CSF albumin were measured using immunonephelometry on a Beckman Immage immunochemistry system (Beckman Instruments, Beckman Coulter, Brea, CA, USA). The ratio between CSF albumin (mg/L) and serum albumin (g/L) was used as a measure of the BBB function. Apolipoprotein E gene (APOE) genotyping was performed by minisequencing.26

2.5 Statistical analysis

SPSS version 25 (IBM Corp., Armonk, NY, USA) was used for all statistical procedures. The descriptive statistical results are given as the mean and SD, if not otherwise stated. Between-group differences were assessed using the Kruskal-Wallis test for multiple variables, followed by the Mann-Whitney U test for pairwise comparisons of continuous variables and using chi-square tests for categorical variables. The relationships between sensitivity and specificity between study groups were described using receiver-operator characteristic (ROC) analysis. In these analyses, we calculated area under the ROC curve (AUROC) and 95%CIs. Correlations were sought using the Spearman rank order correlation test. Statistical significance was obtained if the two-tailed P-value was < .05.

2.6 Ethical considerations

The study was approved by the regional ethical committee in Gothenburg (# 091-99, T479-11 and 2020-06733). Oral and written informed consent was obtained from all study participants. The study was performed in compliance with the Declaration of Helsinki.

3 RESULTS

3.1 Clinical characteristics

The clinical characteristics of the patients and controls are given in Table 1 and Figure S1. The proportion of men was higher in the SSVD group than in the AD group. Mean age was higher in all the patient groups compared with the controls (Figure S1A). In addition, patients with mixed AD/SSVD had higher mean age than SSVD and AD patients. Education level was lower (Figure S1B), and the scores of the neuropsychological tests (MMSE, RAVLT delayed recall, TMT-A, and TMT-B; Figure S1C-SF) were more impaired in the patient groups compared with the control group. Furthermore, SSVD patients had higher MMSE scores than patients with mixed AD/SSVD and higher RAVLT delayed-recall scores than AD and mixed AD/SSVD patients. Per design, the core CSF AD biomarker levels (Aβ42, t-tau, and p-tau181) were abnormal in the AD or AD/SSVD groups compared with the SSVD and control groups (Figure S1G-SI). Nevertheless, SSVD patients had higher CSF t-tau level than the controls. Finally, the AD and SSVD groups had higher prevalence of APOE ε4 allele than the control group, and AD patients also had higher prevalence of APOE ε4 allele than SSVD patients (Table 1).

3.2 Fluid biomarkers

CSF levels of Aβ40, Aβ42, sAPP-α, and sAPP-β are presented in Figure 1 and Table 2. SSVD patients had lower CSF sAPP-β levels compared with the controls, whereas there was no difference between these two groups in terms of other CSF biomarkers (Figure 1E). In addition, CSF sAPP-β levels were significantly lower in SSVD patients compared with AD patients. The average levels of CSF sAPP-β were lower in SSVD than in mixed AD/SSVD, but this difference was not statistically significant. As expected, patients with AD and mixed AD/SSVD had reduced CSF Aβ42 levels (Figure 1C), and also lower Aβ42/Aβ40 ratios than both SSVD patients and healthy controls (Figure 1F-G). Moreover, the CSF/serum albumin ratio was elevated in the SSVD group (Figure 1H).

3.3 Biomarker correlations

CSF/serum albumin ratio was not correlated with CSF levels of sAPP-β or sAPP-α in the study population (n = 170; r = −0.11 and r = −0.03, respectively) or in any of the study groups (data not shown). CSF sAPP-β level correlated positively with CSF sAPP-α level in the total study population (r = 0.66, P < .001) as well as in all study groups (SSVD: r = 0.75, P < .001; AD: r = 0.75, P < .001; mixed AD/SSVD: r = 0.57, P < .001; and control: r = 0.48, P < .001).
3.4 | Diagnostic accuracy of CSF sAPP-β and CSF/serum albumin ratio

Next, we performed ROC curve analyses to further evaluate CSF sAPP-β, which was different in SSVD compared with healthy controls and AD patients. We found that CSF sAPP-β moderately differentiated SSVD from controls (AUROC 0.65, 95% CI: 0.53 to 0.78) and SSVD from AD (AUROC 0.69, 95% CI: 0.58 to 0.81), whereas it did not distinguish SSVD from mixed AD/SSVD (AUROC 0.59, 95% CI: 0.45 to 0.73).

We observed that CSF/serum albumin ratio, which was different in SSVD compared with all other study groups, had moderate ability to separate SSVD from controls (AUROC 0.70, 95% CI: 0.58 to 0.83), SSVD from AD (AUROC 0.75, 95% CI: 0.64 to 0.85), and SSVD from mixed AD/SSVD (AUROC 0.66, 95% CI: 0.53 to 0.79).

Finally, we included both CSF sAPP-β and CSF/serum albumin ratio in the analyses. This panel (CSF sAPP-β and CSF/serum albumin ratio) had a somewhat improved ability to distinguish SSVD from controls (AUROC 0.73, 95% CI: 0.61 to 0.85), SSVD from AD (AUROC 0.78, 95% CI: 0.68 to 0.88), and SSVD from mixed AD/SSVD (AUROC 0.66, 95% CI: 0.53 to 0.79).

4 | DISCUSSION

In this study, CSF APP metabolites and CSF/serum albumin ratio were examined in patients with SSVD, mixed AD/SSVD, and AD at an outpatient memory clinic. We found that sAPP-β was decreased in the SSVD group compared with both the control and AD groups. BBB function, as measured by the CSF/serum albumin ratio, was increased in the SSVD in comparison with all other study groups, whereas the groups with AD pathology did not differ from healthy controls. Overall, ROC curve analyses using sAPP-β, CSF/serum albumin ratio, and their combinations showed a moderate ability to separate SSVD from the other groups. These findings support the notion of SSVD being a separate dementia form and is line with Consensus Statement of Subcortical Small Vessel Disease and the classification of the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) in which SSVD dementia, denominated subcortical ischemic vascular dementia, is one of the VCD forms. VICCCS used the Delphi method among clinicians and researchers in the field to determine the nosological structure of major VCI. In addition to SSVD, the following were identified as relevant major VCI subtypes: poststroke dementia (PSD), multi-infarct dementia (MID), and mixed dementias. Because
Cerebrospinal fluid (CSF) levels of \( \text{A}_\beta_{x-38}, \text{A}_\beta_{x-40}, \text{A}_\beta_{x-42}, \text{sAPP-}\alpha, \) and \( \text{sAPP-}\beta, \) as well as \( \text{A}_\beta_{x-42/x-38}, \text{A}_\beta_{x-42/x-40}, \) and CSF/serum albumin ratios in patients and controls. Values are given as means (SD). Different letters above each group correspond to significant differences of \( P < .05. \) For details regarding significance values, see Table 2. SSVD, subcortical small vessel disease; AD, Alzheimer’s disease; \( \text{A}_\beta, \) amyloidbeta; sAPP, soluble amyloid precursor protein.
there was an absence of stroke episodes or no close time relationship between stroke episodes and development of cognitive impairment in the present study, no patients exhibited PSD or MID.

Our study is the first one measuring CSF sAPP-β in SSVD. Previously, sAPP-β has been investigated in only a few patient cohorts. In the LADIS (Leukoaraoisis and Disability in the Elderly) study, sAPP-β was negatively correlated with WMH volume. In another study, CSF sAPP-β levels were lower in poststroke patients than in patients with subjective cognitive impairment (SCI)/MCI patients, and the chronic white matter lesions correlated with reduced levels of sAPP-β in both patient groups. Furthermore, CSF sAPP-β was reduced in patients with frontotemporal lobar degeneration compared to AD and healthy controls, and sAPP-β was correlated positively with cortical thickness. Of interest, it was recently shown that β-secretase is expressed less in postmortem hippocampus of CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) patients compared to sporadic and familial AD cases, which could explain low levels of sAPP-β in diseases affecting the brain vasculature. Although the earlier studies indicate that low levels of sAPP-β are involved in the pathogenesis of vascular diseases, more knowledge regarding the neurobiological functions of sAPP-β is needed to explain the results in our study.

APP is expressed abundantly in the brain and has synaptogenic and neurotrophic properties, but limited knowledge is available on neuropathological functions of soluble APP species. Both sAPP-α and sAPP-β have been shown to decrease cell adhesion and increase axon elongation when given to neuronal cultures. However, although sAPP-α has been shown to protect neurons against Aβ oligomer-induced dendritic spine loss and increased tau phosphorylation, sAPP-β does not have such protective functions. On the other hand, sAPP-β serves as a death receptor 6 ligand and regulates neuronal cell death and axonal pruning. Considering the role of sAPP-β in axonal elongation, the low levels of sAPP-β in SSVD patients could suggest that these patients lack a so far unknown protective repair mechanism mediated by sAPP-β.

The present study adds to the involvement of BBB dysfunction in VCD and SSVD. However, to our knowledge, there is only one previous CSF study on pure SSVD, which also includes pure AD and mixed AD/SSVD. In that study, albumin ratio was increased in cerebral small vessel disease with cognitive impairment without a CSF AD signature, whereas in patients with small vessel disease and a CSF AD signature, albumin ratio was altered to a smaller degree. Although the diagnostic entrance was partially different from that in our study, the results are in agreement with our findings, suggesting that increased albumin ratio is more typical for SSVD compared with mixed dementia.

To date, the relationship between sAPP-β and BBB dysfunction has not been clarified, but APP metabolites have been shown to regulate BBB function (reviewed in Ristori et al.). The presence of BBB dysfunction in SSVD suggests that the pathology may be closely related to changes in the tight junctions of the vessel wall. A possible link between BBB and APP processing could be matrix metalloproteinases (MMP), which in previous studies have been found to be increased in SSVD and VCD. MMPs are thought to contribute to the BBB dysfunction by disrupting the integrity of the BBB, and MMPs have been shown to be associated with BBB dysfunction in SSVD. In the last years, MMPs have also been suggested to alter the metabolism and processing of APP, which could underlie the altered CSF levels of sAPP-β in SSVD.

**TABLE 2**  Cerebrospinal fluid (CSF) levels of Aβx-38, Aβx-40, Aβx-42, sAPP-α, and sAPP-β, as well as Aβx-42/x-38, Aβx-42/x-40, and CSF/serum albumin ratios in patients and controls

| Variable | SSVD (n = 30) | AD (n = 60) | Mixed AD/SSVD (n = 35) | Control (n = 45) | P-value between groups |
|----------|--------------|------------|------------------------|-----------------|-----------------------|
| Aβx-38 (ng/L) | 2035 (664) | 2242 (658) | 2467 (874) | 2208 (672) | .21 |
| Aβx-40 (ng/L) | 5210 (1304) | 5639 (1454) | 6200 (1967) | 5506 (1480) | .29 |
| Aβx-42 (ng/L) | 459 (180) | 254 (77) | 269 (99) | 532 (192) | <.001 |
| sAPP-α (ng/mL) | 252 (102) | 316 (136) | 309 (134) | 300 (123) | .13 |
| sAPP-β (ng/mL) | 462 (235) | 636 (405) | 566 (394) | 546 (211) | .02 |
| Ratios | \(\frac{Aβx-42}{x-38}\) | 0.229 (0.058) | 0.118 (0.036) | 0.114 (0.035) | 0.244 (0.053) | <.001 |
| \(\frac{Aβx-42}{x-40}\) | 0.087 (0.021) | 0.045 (0.009) | 0.044 (0.010) | 0.096 (0.018) | <.001 |
| CSF/serum albumin | 7.9 (2.6) | 5.8 (2.2) | 6.6 (2.8) | 6.3 (2.3) | .001 |

Values are given as means (SD). Between-group differences were examined using the Kruskal-Wallis test for multiple comparisons followed by the Mann-Whitney U test for pairwise comparisons. SSVD, subcortical small vessel disease; AD, Alzheimer’s disease; Aβ, amyloid-beta; sAPP, soluble amyloid precursor protein.

\(P < .001\) versus AD.
\(P < .001\) versus mixed AD/SSVD.
\(P < .001\) versus control.
\(P < .05\) versus control.
\(P < .01\) versus AD.
\(P < .01\) versus control.
\(P < .05\) versus mixed AD/SSVD.
In our study, we could not find any statistical correlation between BBB function and either of the two sAPP proteins, indicating that they are not directly connected.

In the present study, we also measured Aβ isoforms Aβ40, Aβ42 and their ratios in CSF. Aβ40 and Aβ42 are produced at relatively low levels compared with Aβ40, which is the most abundant Aβ isoform. Aβ40 is the most soluble of the three peptides and is seldom seen in senile plaques in sporadic AD postmortem brains, but can be detected in the brain vasculature. Levels of Aβ40 and Aβ42 are high in postmortem AD brain tissue. Aβ40 is moderately aggregation-prone and the main component of vascular amyloid. However, the most aggregation-oriented Aβ peptide is Aβ42, which is accumulated in amyloid plaques linked to AD. A previous study has shown that CSF Aβ42 was lower in MCI patients later developing SVD, than in controls, but CSF Aβ42 levels were even lower in MCI patients later developing AD or mixed AD/SSVD. In our study, we used Aβ42 for diagnostic purposes. Aβ42 could therefore not be used for outcome evaluation, and as a consequence, the low levels of Aβ42 in both AD and mixed AD/SSVD are expected.

The absence of differences between the patients and controls with regard to Aβ40 and Aβ42 suggests that these proteins are not involved in disease processes resulting in AD or SVD. In a study of patients with AD and vascular dementia without stroke, which does not directly correspond to our specific SVD group, increased levels of Aβ40 were found in comparison with nondemented controls. Furthermore, one study showed lower CSF levels of Aβ40 and Aβ42 in subcortical vascular dementia patients compared to levels in controls and AD patients, which are at variance with our results. Different aims, diagnostic procedures, and analysis methods between the studies may explain the divergent results.

In our study, the neuropsychological outcome measures TMT-A and TMT-B did not differ between the various disease entities, which may question the notion that executive dysfunction and mental speed are key features of SVD dementia. However, executive dysfunction is a complex phenomenon with several components. One possibility could be that our SVD and mixed AD/SSVD groups exhibited other difficulties in planning, initiating, and implementing than those represented by the TMT tests. Another explanation for the lack of differences between groups with regard to TMT could be that the degree of the disease was sufficiently pronounced as to affect the whole range of cognitive domains.

4.1 | Strengths and limitations

A strength of our study is that the patients were systematically diagnosed using a combination of basic characteristics and biomarkers in patients seeking help at a single memory clinic. Limitations include the lack of neuropathological verification of the clinical entities and that the biomarkers used for diagnosis of SVD dementia and AD dementia belonged to different modalities and varied with regard to precision of scaling (semiquantitative assessment of WMHs vs quantitative measurement of biochemical markers). Another limitation is the lack of longitudinal data, which makes it difficult to examine cause-and-effect relationships.

4.2 | Future research

The establishment of a diagnostic protocol, including the use of AD biomarkers, will in the future allow for continuing biomarker analyses on this cohort. This is of potential importance because biomarker studies on pure SSVD cases are still limited. Moreover, the Gothenburg MCI cohort being a longitudinal study could allow for future investigation of BBB dysfunction and sAPP-β in controls and in patients over time, both before and after the conversion to dementia stages. Moreover, the cohort could also be of importance for detailed molecular analyses of disease processing in the future, by using state-of-the-art molecular techniques, including proteomics and lipidomics.

5 | CONCLUSION

In conclusion, at an outpatient memory clinic, patients with SVD exhibited reduced levels of sAPP-β and disturbances of the BBB. This biochemical pattern is different from that of AD patients and to some degree also from that of mixed AD/SSVD. Our findings are speaking in favor of the conception that SVD is a distinct VCD form.

ACKNOWLEDGMENTS

This work was supported by the Swedish state under the agreement between the Swedish government and the county councils, and the ALF agreement (ALFGBG-724331 [Petronella Kettunen], ALFGBG-722371 [Johan Svensson], ALFGBG-720931 [Henrik Zetterberg], ALFGBG-715986 [Kaj Blennow], and ALFGBG-720661 [Anders Wallin]). Petronella Kettunen is supported by the Swedish Alzheimer Foundation; Demensfonden, Sweden; Gun & Bertil Stohnes Stiftelse, Sweden; Stiftelsen för Gamla Tjänarinnor, Sweden; Gunvor och Josef Åhers stiftelse, Sweden; Formas, a Swedish government research council for sustainable development; Hedlunds stiftelse, Sweden; Stiftelsen Hjalmar Svenssons Forskningsfond, Sweden; Stiftelsen Längmanska kulturfonden, Sweden; Magnus Bergwalls Stiftelse, Sweden; Stiftelsen Psykiatriska Forskningsfond, Sweden; The Royal Society of Arts and Sciences in Gothenburg, Sweden; Sweden’s innovation agency Vinnova; The Wenner-Gren Foundations, Sweden; Wilhelm & Martina Lundgrens Vetenskapsfond, Sweden; and Åhlers stiftelse, Sweden. Funding also came from Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse, Sweden [Anders Wallin], Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research
and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIAD); and the UK Dementia Research Institute at UCL. Kaj Blennow is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).

CONFLICTS OF INTEREST
Petronella Kettunen, Maria Bjerke, Carl Eckerström, and Johan Svensson: no conflicts of interest. Michael Jonsson: Consulting fees for assignment as paid advisory board member for Biogen 2020-2021. Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alexion, Eisai, Denali, Roche, Wave, Samumed, Siemens Healthineers, Pintecx Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Kaj Blennow has served as a consultant, on advisory boards, or on data-monitoring committees for Abcam, Alexion, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this article. Anders Wallin: Lecture fees from Lundbeck.

AUTHOR CONTRIBUTIONS
Petronella Kettunen, Maria Bjerke, Johan Svensson, and Anders Wallin: study design, data analysis, data interpretation, drafting of manuscript, and manuscript revision. Henrik Zetterberg and Kaj Blennow: sample analysis. Carl Eckerström, Michael Jonsson, Henrik Zetterberg, and Kaj Blennow: manuscript revision. All authors have accepted the last version of the manuscript.

REFERENCES
1. Wallin A, Román GC, Esiri M, et al. Update on vascular cognitive impairment associated with subcortical small-vessel disease. J Alzheimer’s Dis. 2018;62:1417-1441.
2. Chui H. Dementia due to subcortical ischemic vascular disease. Clin Cornerstone. 2001;3:40-51.
3. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838.
4. Walsh J, Tozer DJ, Sari H, et al. Microglial activation and blood-brain barrier permeability in cerebral small vessel disease. Brain. 2021;144:1361-1371.
5. Wardlaw JM, Makin SJ, Valdés Hernández MC, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimer’s Dement. 2017;13:634.
6. Zhang CE, Wong SM, van de Haar HJ, et al. Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease. Neurology. 2017;88:426-432.
7. Herrmann P, Romero C, Schmidt C, Reis C, Zerr I. CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One. 2014;9:e105000.
8. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184-185.
9. Hauw JJ, De Girolami U, Zekry D. The neuropathology of vascular and mixed dementia and vascular cognitive impairment. Handb Clin Neurol. 2008;89:687-703.
10. Eckerström C, Eckerström M, Göthlin M, et al. Characteristic biomarker and cognitive profile in incipient mixed dementia. J Alzheimer’s Dis. 2020;73:597-607.
11. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673-684.
12. Janelidze S, Zetterberg H, Mattsson N, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ42 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154-165.
13. Goos JD, Teunissen CE, Veerhuis R, et al. Microbleeds relate to altered amyloid-beta metabolism in Alzheimer’s disease. Neurobiol Aging. 2012;33:1011. e1-9.
14. Johansson P, Mattsson N, Hansson O, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. J Alzheimer’s Dis. 2011;24:537-546.
15. Bjerke M, Jonsson M, Nordlund A, et al. Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS Substudy. Dement Geriatr Cogn Dis Extra. 2014;4:385-394.
16. Jonsson M, Zetterberg H, van Straaten E, et al. Cerebrospinal fluid biomarkers of white matter lesions—cross-sectional results from the LADIS study. Eur J Neurol. 2010;17:377-382.
17. Wallin A, Nordlund A, Jonsson M, et al. The Gothenburg MCI study: design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab. 2016;36:114-131.
18. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988;24:661-663.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939-944.
20. Dubois B, Feldman M, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-629.
21. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228-234.
22. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. Neurot Transm Suppl. 2000;59:23-30.
23. Wahlund L, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-1322.
24. Skrobot OA, McKnight AJ, Passmore PA, et al. A validation study of vascular cognitive impairment genetics meta-analysis findings in an independent collaborative cohort. J Alzheimer’s Dis. 2016;53:981-989.
25. Wallin A, Nordlund A, Jonsson M, et al. Alzheimer’s disease—subcortical vascular disease spectrum in a hospital-based setting: overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab. 2016;36:95-113.
26. Blennow K, Ricksten A, Prince J, et al. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm. 2000;107:1065-1079.
28. Selnes P, Blennow K, Zetterberg H, et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 2010;7:10.

29. Alcolea D, Vilaplana E, Suárez-Calvet M, et al. CSF sAPPα

30. Illán-Gala I, Pegueroles J, Montal V, et al. APP-derived peptides reflect neurofilament light in frontotemporal lobar degeneration. Neurology. 2017;89:178-188.

31. Chacon-Quintero MV, Pineda-Lopez LG, Villegas-Lanau CA, Posada-Duque R, Cardona-Gomez GP. Beta-Secretase 1 underlies reactive astrocytes and endothelial disruption in neurodegeneration. Front Cell Neurosci. 2021;15:656832.

32. Chasseigneaux S, Allinquant B. Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J Neurochem. 2012;120(Suppl 1):99-108.

33. Chasseigneaux S, Dinc L, Rose C, et al. Secreted amyloid precursor protein β and secreted amyloid precursor protein α induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One. 2011;6:e16301.

34. Tackenberg C, Nitsch RM. The secreted APP ectodomain sAPPα, but not sAPPβ, protects neurons against Aβ oligomer-induced dendritic spine loss and increased tau phosphorylation. Mol. brain. 2019;12:27.

35. Nikolaea A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death after distinct caspases. Nature. 2009;457:981-989.

36. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand. 1990;81:318-322.

37. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand. 1990;81:318-322.

38. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand. 1990;81:318-322.

39. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease—systematic review and meta-analysis. Neurobiol Aging. 2009;30:337-352.

40. Ristori E, Donnini S, Ziche M. New insights into blood-brain barrier maintenance: the homeostatic role of β-amyloid precursor protein in cerebral vasculature. Front Physiol. 2020;11:1056.

41. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimer’s Dis. 2011;27:665-676.

42. Candelario-Jalil E, Thompson J, Taheri S, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke. 2011;42:1345-1350.

43. Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36:1481-1507.

44. Paumier JM, Py NA, García-González L, et al. Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking. FASEB J. 2019;33:2910-2927.

45. Czirr E, Cottrell BA, Leuchtenberger S, et al. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem. 2008;283:17049-17054.

46. Reinert J, Martens H, Huettenrauch R, et al. Ap38 in the brains of patients with sporadic and familial Alzheimer’s disease and transgenic mouse models. J Alzheimer’s Dis. 2014;39:871-881.

47. Svedberg MM, Hall H, Hellström-Lindahl E, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347-357.

48. Ozawa K, Tomiyama T, Maat-Schieman ML, Roos RA, Mori H. Enhanced Abeta40 deposition was associated with increased Abeta42-43 in cerebral vasculature with Dutch-type hereditary cerebral hemorrhage with amyloidosis (HCHWA-D). Ann N Y Acad Sci. 2002;977:149-154.

49. Portelius E, Bogdanovic N, Gustavsson MK, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta Neuropathol. 2010;120:185-193.

50. Bjerke M, Andreasson U, Rolstad S, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord. 2009;28:348-356.

51. Roman GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis Assoc. 1999;13(Suppl 3):S69-S80.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Kettunen P, Bjerke M, Eckerström C, et al. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease. Alzheimer’s Dement. 2022;14:e12296. https://doi.org/10.1002/dad2.12296